MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.
"These three presentations demonstrate our commitment to furthering the body of scientific knowledge surrounding SB 9200 and its antiviral activity," said R.P. Iyer, Ph.D., Co-founder and Chief Scientific Officer of Spring Bank. "The data being presented support our pipeline of clinical-stage candidates and provide important insights that are relevant to our ongoing clinical development in viral infections, including HBV and HCV, among others. ICAR is a prestigious global antiviral conference and we are proud to have been selected as one of the presenting companies."
The details of Spring Bank's presentations are below:
Oral poster presentations
- "Activation of Intracellular Viral Sensors by the Anti-Hepatitis Agent SB 9200 Implications for Broad-Spectrum Antiviral Activity"
- "Preclinical Studies of SB 9200 as an Antiviral Agent Against HBV and HCV"
- "SB 9200, a Novel Anti-HBV agent In Vitro Combination Studies and Pharmacodynamic studies in Woodchucks"
For more information about ICAR please visit: http://www.isar-icar.com/?page=27icar
About SB 9200
SB 9200 is a novel clinical candidate being developed for the treatment of chronic HBV and HCV infections and is based on Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform. SB 9200 has unique mechanisms of antiviral action involving the selective activation of the host-immune response in virus-infected cells. Unlike other classes of drugs for Hepatitis infections that act directly on the virus, SB 9200 uniquely targets host cytosolic sensor proteins, RIG-I and NOD2, which leads to the selective modulation of the host immune response in virus-infected cells.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is engaged in the discovery and development of an entirely new class of safer and more effective medicines based on the Company's proprietary SMNH, "Small Molecule Nucleic Hybrid" technology program. SB 9200, a potential breakthrough drug for the treatment of HCV and HBV, is the Company's most advanced drug under development. The Company also has antiviral programs for the treatment of other single and double stranded RNA viruses such as Respiratory Syncytial Virus (RSV), Norovirus and a Broad spectrum antiviral. Spring Bank also has an early anti-inflammatory program targeting chronic obstructive pulmonary disease (COPD) and asthma.
Douglas J. Jenson
President and Chief Executive Officer
(508) 473-5993 x105
SOURCE Spring Bank Pharmaceuticals, Inc.